PDE5A and pulmonary arterial hypertension: Sildenafil, a selective PDE5-inhibitor, has been extensively studied for the treatment of erectile dysfunction (ED) [22], pulmonary arterial hypertension (PAH) [23], microvascular diseases [24,25], platelet function [26,27,28], and angiogenesis [29,30].